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Abstract. The use of purified and overexpressed alcohol dehydrogenases to synthesize enantiopure 
fluorinated alcohols is shown. Performing the bioreductions with ADH-A from Rhodococcus ruber 
overexpressed in E. coli, no external cofactor was necessary to obtain the enantiopure (R)-derivatives. 
Employing Lactobacillus brevis ADH, it was possible to achieve the synthesis of enantiopure (S)-
fluorohydrins at 0.5 M substrate concentration. Furthermore, due to the activated character of these 
substrates, it was not necessary a huge excess of the hydrogen donor. 
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Fluorinated compounds have a central role nowadays in pharmaceuticals, agrochemicals, radiotracers, 
and high performance materials.
1
 Particularly, vicinal fluoro alcohols (fluorohydrins), also present 
interesting properties as liquid crystals
2
 and as precursors of natural product analogues such as steroids 
or carbohydrates,
3
 since it is well-known that the introduction of C-F bonds can modulate their 
physicochemical properties, including bioavailability, lipophilicity, and oxidative stability. 
To obtain these derivatives in a selective fashion, recently several strategies have been described
4
 and 
among them, the aperture of racemic or meso-epoxides,
5
 the C-C formation of (partially) fluorinated 
building blocks
6
 or the reduction of α-fluoro ketones7 can be highlighted. Although remarkable 
improvements have been done in these fields in the past years, the use of enzymes
8
 to synthesize chiral 
alcohols is very competitive in terms of selectivity and environmentally friendly conditions. Thus, in the 
particular case of the bioreduction of fluorinated ketone precursors, historically whole cells were 
employed to obtain enantioenriched fluorohydrins,
9
 but due to the presence of several enzymes with 
opposite stereopreference, in many examples it was not possible to obtain the enantiopure alcohols. 
Therefore, in the last few years the use of isolated or overexpressed alcohol dehydrogenases (ADHs)
10
 in 
combination with very efficient nicotinamide recycling systems has been successfully shown to 
synthesize fluorinated alcohols in excellent yields and ee.
11
 
Most of the biocatalytic examples achieved until now are related with the reduction of 2-
fluoroacetophenone and 2,2,2-trifluoroacetophenone,
9,11
 so due to the relevance of chiral aromatic 
fluorohydrins,
2,12
 we became interested in achieving a systematic study about the application of purified 
and overexpressed ADHs with opposite stereopreference to obtain both enantiopure antipodes of the 
fluorohydrin derivatives. 
A series of α-fluoroacetophenones (3b-l) were synthesized through bromination of the corresponding 
acetophenones 1 with N-bromosuccinimide (NBS) and p-toluenesulfonic acid (p-TsOH) in acetonitrile 
(MeCN) at 50ºC to obtain the α-bromo ketones 2,13 followed by nucleophilic substitution using KF and 
ZnF2 in MeCN at 100ºC (Scheme 1).
14
 2-Fluoroacetophenone (3a) was prepared as previously 
 3 
described.
15
 The synthesis of the corresponding racemic fluorohydrins was performed by simple 
treatment of the ketones with NaBH4 in MeOH at 0ºC. 
 
Scheme 1. Synthesis of α-fluoroacetophenone derivatives 3a-l 
 
 
Due to our previous expertise in ADH-catalyzed reductions,
13,16
 we selected a series of purified and 
overexpressed biocatalysts (see the Experimental Section), to achieve the transformations using ketones 
3a-l as substrates, together with fluorinated α-bromoacetophenones 2b and 2i, and also 2,2-difluoro- (4) 
and 2,2,2-trifluoroacetophenone (5) to compare the activity and selectivity with the monofluorinated 
compound 3a. Buffer Tris.HCl 50 mM pH 7.5 was selected as appropriate medium, except for 
brominated compounds 2b and 2i where Tris.H2SO4 was employed to avoid undesired SN2 reactions.
13
 
Furthermore, 1 mM of the corresponding nicotinamide cofactor was also added and 2-propanol or 
glucose with glucose dehydrogenase (GDH) to recycle it. After enzymatic screening, overexpressed 
ADH-A from Rhodococcus ruber in E. coli (E. coli/ADH-A),
17
 and commercially available ADH from 
Lactobacillus brevis (LBADH)
18
 were chosen as the best biocatalysts in terms of activity and selectivity. 
The employment of these enzymes is highly desirable since they can work under the ‘coupled-substrate’ 
approach using 2-propanol to recycle the cofactor, diminishing processes costs and allowing higher 
substrate concentrations due to better ketone solubility in the aqueous buffer. Furthermore, due to the 
opposite stereopreference they show, it was possible to get access to both alcohol enantiomers. 
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Therefore, substrates 2b, 2i, 3a-l, 4 and 5 (30 mM) were subjected under these biocatalytic conditions 
obtaining excellent results with both enzymes (Table 1). 
 
Table 1. Bioreductions of fluorinated ketones (30 mM) using E. coli/ADH-A and LBADH
a
 
 
entry ketone E. coli/ADH-A LBADH 
  c (%)
b
 ee (%)
c,d
 c (%)
b
 ee (%)
c,d
 
1 2b >99 >99 (R) >99 >99 (S) 
2 2i >99 >99 (R) >99 >99 (S) 
3 3a >99 >99 (R) >99 >99 (S) 
4 3b >99 >99 (R) >99 >99 (S) 
5 3c >99 >99 (R) >99 >99 (S) 
6 3d >99 >99 (R) 99 >99 (S) 
7 3e >99 >99 (R) >99 >99 (S) 
8 3f >99 >99 (R) >99 >99 (S) 
9 3g >99 >99 (R) >99 >99 (S) 
10 3h >99 >99 (R) >99 >99 (S) 
11 3i >99 >99 (R) >99 >99 (S) 
12 3j >99 >99 (R) >99 >99 (S) 
13 3k >99 >99 (R) >99 >99 (S) 
14 3l >99 >99 (R) >99 >99 (S) 
15 4 >99 >99 (R) >99 >99 (S) 
16 5 >99 >99 (R) >99 >99 (S) 
a
 For experimental details, see Experimental Section. 
b
 Measured by GC. 
c
 Measured by chiral GC. 
d
 
Change in Cahn-Ingold-Prelog (CIP) priority. 
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Gratefully, in every case the substrate was completely transformed into the enantiopure (R)- or (S)-
alcohol when using ADH-A or LBADH, independently it bore electron withdrawing or electron 
donating groups at meta- or para-positions. Also di- or trifluorinated ketones 4 and 5 afforded perfect 
conversions and ee with both biocatalysts. 
One additional advantage of working with overexpressed ADH preparations is the possibility to avoid 
the use of external cofactor when performing the bioreductions.
19
 Therefore, some of these ketones were 
tested at higher substrate concentration with E. coli/ADH-A without the addition of external NADH 
(Table 2). It was interesting to observe that in some cases the enantiopurity of the final alcohols slightly 
decreased. This could be probably due to the action of other NADP-dependent ADHs from the host 
organism that in the absence of additional NADH could compete with ADH-A diminishing the overall 
selectivity. Moreover, it was demonstrated that even at high concentrations such as 200 mM, 
conversions remained quantitative. 
 
Table 2. Bioreductions of fluorinated ketones using E. coli/ADH-A and 2-PrOH (10% v v
-1
) without the 
addition of external NADH (t= 24 h)
a
 
entry ketone concentration (mM) c (%)
b
 ee (%)
c,d
 
1 3a 200 >99 >99 (R) 
2 3b 200 >99 97 (R) 
3 3c 200 >99 98 (R) 
4 3e 200 >99 >99 (R) 
5 4 200 >99 94 (R) 
6 5 100 >99 >99 (R) 
a
 For experimental details, see Experimental Section. 
b
 Measured by GC. 
c
 Measured by chiral GC. 
d
 
Change in CIP priority. 
 
In a next step, we decided to increase the substrate concentration keeping constant the quantity of 
LBADH in the presence of 1 mM of the nicotinamide cofactor and just increasing the amount of 2-
 6 
PrOH, although due to the fact that α-halogenated ketones can be quasi-irreversibly reduced,20 it was not 
necessary a huge excess of the hydrogen donor. A selection of the results obtained is shown in Figure 1. 
 
 
Figure 1. Examples of enantiopure fluorinated alcohols obtained at 0.5 M substrate concentration with 
LBADH and 2-PrOH (t= 24 h). For other results, see Supporting Information. 
 
Several enantiopure fluorinated alcohols were achieved at 0.5 M concentration with excellent 
conversions in the presence of 3 U of the enzyme and 1 mM NADP
+
. In these examples, 20% v v
-1
 of 
the hydrogen donor 2-PrOH was employed, approximately a molar excess of 5:1 with regards to the 
ketone substrate, confirming that the bioreduction of these derivatives was thermodynamically favored. 
(R)-6b is a precursor of cholesterol absorption inhibitors (CAI) such as AZD4121 or ezetimibe 
(Scheme 2), a class of compounds that have attracted attention for the treatment of 
hypercholesterolemia, related to several diseases as atherosclerosis.
21
 This alcohol was recently 
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synthesized via asymmetric reduction with (R)-2-methyloxazaborolidine in the presence of borane-
dimethyl sulfide complex in THF at 0ºC.
22
 With regards to biocatalyzed synthesis, Zhu and co-workers 
obtained the enantiopure (S)-alcohol using an isolated ADH from Candida magnolia with glucose and 
GDH to recycle the nicotinamide cofactor.
23 
 
Scheme 2. (R)-6b, a precursor of cholesterol absorption inhibitors such as ezetimibe 
 
 
Due to the relevance of this bromohydrin, the E. coli/ADH-A catalyzed bioreduction of 2b was 
performed at 260 mg-scale with a 100 mM substrate concentration, obtaining enantiopure (R)-6b after 
purification with 70% yield. 
Overall, with the systematic study shown here it was demonstrated that ADH-catalyzed hydrogen 
transfer reduction of α-fluoro ketones is a very convenient method to synthesize both alcohol antipodes 
in an enantiopure form at high substrate concentrations with excellent conversions. Thus, when 
performing the bioreduction in the presence of overexpressed enzymes it was also possible to avoid the 
use of external nicotinamide cofactor. Due to the nature of these activated ketones, it was not necessary 
the employment of a huge excess of the hydrogen donor. 
 
Experimental Section 
General. Acetophenones 1e, 1i, 1j, 1k, and 1l, α-bromoacetophenones 2b, 2c, 2d, 2f, 2g, and 2h, 
difluorinated ketone 4 and trifluorinated derivative 5 were obtained from commercial sources. All other 
reagents and solvents were of the highest quality available. LBADH from Lactobacillus brevis and GDH 
were obtained from commercial sources. The following overexpressed enzymes in E. coli have been 
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kindly provided by Prof. Wolfgang Kroutil from the University of Graz (Austria): ADH-A from 
Rhodococcus ruber (E. coli/ADH-A), ADH-T from Thermoanaerobium sp. (E. coli/ADH-T), SyADH 
from Sphingobium yanoikuyae (E. coli/SyADH), RasADH from Ralstonia sp. (E. coli/RasADH), and 
TeSADH from Thermoanaerobacter ethanolicus (E. coli/TeSADH). 
Chemical reactions were monitored by analytical TLC, performed on silica gel 60 F254 plates and 
visualized by UV irradiation. Flash chromatography was performed using silica gel 60 (230-400 mesh). 
Melting points were taken on samples in open capillary tubes and are uncorrected. IR spectra were 
recorded on an infrared Fourier transform spectrophotometer on NaCl pellets. 
1
H-, 
13
C, 
19
F-NMR, and 
DEPT were obtained using 300 and 400 MHz spectrometers for routine experiments. The chemical 
shifts (δ) are given in ppm and the coupling constants (J) in Hertz (Hz). ESI+ mode was used to record 
mass spectra (MS) and ESI-TOF for HRMS. Gas chromatography (GC) analyses were performed on a 
standard GC chromatograph. Calibration curves were performed with α-fluoro ketones and the 
corresponding fluorohydrins to measure accurately the enzymatic conversions. Optical rotations were 
measured using a standard polarimeter and are quoted in units of 10
-1
 deg cm
2
 g
-1
. For new compounds, 
the indirect assignation of their configuration was based in two convergent criteria: a) the perfect 
stereoselectivity shown by ADH-A and LBADH for the other members of this fluorinated family and 
other similar compounds, and b) the order of the elution peaks in the chiral GC column. 
Synthesis of α-bromoacetophenone derivatives 2. To a solution of the acetophenone derivative 
(15.0 mmol, 1 equiv) in 8 mL of acetonitrile, NBS (2.72 g, 15.3 mmol, 1.02 equiv) and p-
toluenesulfonic acid (2.85 g, 15.0 mmol, 1 equiv) were added. The reaction mixture was stirred for 24 h 
at 50˚C. After that time, the solvent was evaporated under reduced pressure. Then, a water solution of 
saturated NaHCO3 (30 mL) was added and the solution was extracted with dichloromethane (3 x 30 
mL). The organic layers were combined and dried over Na2SO4. The solvent was evaporated and the 
residue was subjected to column chromatography (silica gel) using hexanes/CH2Cl2 (from 9:1 to 4:1) as 
eluent. These compounds exhibited physical and spectral data in agreement with those reported.
24
 2e 
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(4.30 g, 88% yield), 2i (2.12 g, 66% yield), 2j (2.88 g, 82% yield), 2k (2.45 g, 71% yield), and 2l (2.60 
g, 71% yield). 
Synthesis of α-fluoroacetophenone derivatives 3. A mixture of KF (4.8 mmol, 1.5 equiv), ZnF2 (4.8 
mmol, 1.5 equiv) in 7 mL of acetonitrile was stirred and heated at 100˚C in a sealed heavy-walled Pyrex 
tube for 1 h. Then, a solution of the substrate (3.2 mmol, 1.0 equiv) in acetonitrile (7 mL) was added 
into the reaction mixture. Then it was heated for 24 h at 100˚C. After that time, the solvent was 
evaporated under reduced pressure. Then, water (20 mL) was added and the solution was extracted with 
dichloromethane (3 x 20 mL). The organic layers were combined and dried over Na2SO4. The solvent 
was evaporated and the residue was subjected to column chromatography (silica gel) using 
hexanes/EtOAc (from 95:5 to 90:10) as eluent. These compounds exhibited physical and spectral data in 
agreement with those reported.
14,25
 3b (230 mg, 47% yield), 3c (255 mg, 47% yield), 3d (625 mg, 90% 
yield), 3e (326 mg, 39% yield), 3f (274 mg, 56% yield), 3g (380 mg, 71% yield), 3h (210 mg, 36% 
yield), 3i (265 mg, 53% yield), 3j (367 mg, 66% yield), 3k (368 mg, 68% yield), and 3l (214 mg, 36% 
yield). 
2-Fluoro-4’-iodoacetophenone (3e). White solid; mp: 92.4-95.3˚C; IR (NaCl): 3054, 2987, 1422, 
1265, 972, 896, 741, 666 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.89 (d, J = 8.6 Hz, 2H), 7.63 (d, J = 8.4 
Hz, 2H), 5.49 (d, J = 46.9 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): δ 193.0 (d, J = 15.8 Hz), 138.3, 133.0, 
129.2 (d, J = 2.9 Hz), 102.3, 83.5 (d, J = 182.5 Hz); 
19
F NMR (282 MHz, CDCl3): δ -229.9; MS (ESI
+
, 
m/z): 287 [(M+Na)
+
, 100%], 265 [(M+H)
+
, 30%]; HRMS (ESI
+
, m/z) calculated for C8H6OFINa 
(M+Na)
+
: 286.9365, found: 286.9340. 
3’-Chloro-2-fluoroacetophenone (3j). Yellow oil; IR (NaCl): 3057, 2987, 2933, 1711, 1575, 1428, 
1266, 1229, 1101, 1087, 998, 739, 704 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.91 (m, 1H), 7.79 (m, 1H), 
7.62 (m, 1H), 7.47 (m, 1H), 5.51 (d, J = 46.8 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): δ 192.4 (d, J = 16.0 
Hz), 135.2 (d, J = 11.6 Hz), 134.1, 130.3, 128.1 (d, J = 2.9 Hz), 126.0 (d, J = 2.7 Hz), 83.6 (d, J = 182.7 
Hz); 
19
F NMR (282 MHz, CDCl3): δ -230.1; MS (ESI
+
, m/z): 195 [(M+Na)
+
, 100%], 173 [(M+H)
+
, 
70%]; HRMS (ESI
+
, m/z) calculated for C8H6OClFNa (M+Na)
+
: 194.9992, found: 194.9983. 
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2-Fluoro-3’-methoxyacetophenone (3k). White solid; mp: 55.7-58.8˚C; IR (NaCl): 3054, 2987, 
1710, 1600, 1584, 1432, 1265, 1092, 738, 705 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.42 (m, 3H), 7.18 
(m, 1H), 5.54 (d, J = 46.9 Hz, 2H), 3.88 (s, 3H); 
13
C NMR (75 MHz, CDCl3): δ 193.2 (d, J = 15.2 Hz), 
160.0, 134.9, 129.9, 120.7, 120.2 (d, J = 2.3 Hz), 112.1 (d, J = 2.2 Hz), 83.5 (d, J = 181.4 Hz), 55.5; 
19
F 
NMR (282 MHz, CDCl3): δ -230.8; MS (ESI
+
, m/z): 191 [(M+Na)
+
, 100%], 169 [(M+H)
+
, 85%]; 
HRMS (ESI
+
, m/z) calculated for C9H9O2FNa (M+Na)
+
: 191.0488, found: 191.0479. 
General procedure for the synthesis of the racemic alcohols 6-9. To a solution of the 
corresponding ketone (4.0 mmol) in methanol (5 mL) at 0˚C, sodium borohydride (1.2 mmol) was 
added. When the reduction was completed (according to the TLC), a few drops of 1 M HCl were added. 
The solvent was evaporated under reduced pressure. Then, water (10 mL) was added and the solution 
was extracted with dichloromethane (3 x 10 mL). The organic layers were combined and dried over 
Na2SO4. The solvent was evaporated and the residue was subjected to column chromatography (silica 
gel) using mixtures of hexanes/ethyl acetate (from 9:1 to 4:1) as eluents. These compounds exhibited 
physical and spectral data in agreement with those reported.
23,26
 Isolated yields: 71-95%. 
2-Bromo-1-(3-fluorophenyl)ethanol (6i). White solid; mp: 66.8-69.0˚C; IR (NaCl): 3054, 2987, 
1422, 1265, 1158, 896, 740, 705 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.37 (m, 1H), 7.16 (m, 2H), 7.05 
(tdd, J = 8.4, 2.5, 0.9 Hz, 1H), 4.95 (dd, J = 8.8, 3.3 Hz, 1H), 3.65 (dd, J = 10.5, 3.3 Hz, 1H), 3.55 (dd, J 
= 10.5, 8.8 Hz, 1H), 2.69 (br s, 1H); 
13
C NMR (75 MHz, CDCl3): δ 163.0 (d, J = 245.3 Hz), 142.8 (d, J 
= 27.4 Hz), 130.2 (d, J = 31.8 Hz), 121.6 (d, J = 11.4 Hz), 115.3 (d, J = 83.7 Hz), 113.0 (d, J = 89.0 Hz), 
73.1, 39.9; 
19
F NMR (282 MHz, CDCl3): δ -112.2; [α]D
20
 = +41.0 (c 1.13, CHCl3), ee >99% (S).
27
 
1-(4-Chlorophenyl)-2-fluoroethanol (7c).
26d
 [α]D
20
 = +42.9 (c 1.67, CHCl3), ee >99% (S). 
2-Fluoro-1-(4-iodophenyl)ethanol (7e). Light yellow solid; mp: 42.3-45.0˚C; IR (NaCl): 3055, 2987, 
1422, 1265, 896, 740, 705 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.73 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 
8.2 Hz, 2H), 5.00 (m, 1H), 4.60-4.28 (m, 2H), 2.52 (br s, 1H); 
13
C NMR (75 MHz, CDCl3): δ 137.8, 
137.7, 128.2, 94.0, 86.8 (d, J = 173.9 Hz), 72.4 (d, J = 20.1 Hz); 
19
F NMR (282 MHz, CDCl3): δ -229.9; 
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MS (ESI
+
, m/z): 289 [(M+Na)
+
, 100%], 249 [(M-OH)
+
, 25%]; HRMS (ESI
+
, m/z) calculated for 
C8H8OFINa (M+Na)
+
: 288.9484, found: 288.9496; [α]D
20
 = +30.3 (c 1.04, CHCl3), ee >99% (S). 
2-Fluoro-1-(4-methylphenyl)ethanol (7f). White solid; mp: 33.8-37.5ºC; IR (NaCl): 3054, 2987, 
1422, 1265, 1090, 1004, 896, 743, 705 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.31 (d, J = 8.1 Hz, 2H), 
7.20 (d, J = 8.0 Hz, 2H), 5.02 (m, 1H), 4.61-4.41 (m, 2H), 2.50 (dd, J = 2.9, 0.8 Hz, 1H), 2.38 (s, 3H); 
13
C NMR (75 MHz, CDCl3): δ 138.3, 135.1 (d, J = 8.2 Hz), 129.3, 126.3, 87.2 (d, J = 173.2 Hz), 72.8 
(d, J = 19.6 Hz), 21.2; 
19
F NMR (282 MHz, CDCl3): δ -220.4; MS (ESI
+
, m/z): 177 [(M+Na)
+
, 100%], 
137 [(M-OH)
+
, 90%]; HRMS (ESI
+
): calculated for C9H11OFNa (M+Na)
+
: 177.0675, found: 177.0686; 
[α]D
20
 = +51.9 (c 1.34, CHCl3), ee >99% (S). 
2-Fluoro-1-(3-fluorophenyl)ethanol (7i). Light yellow oil; IR (NaCl): 3055, 2986, 1594, 1450, 1266, 
1137, 1010, 896, 739, 705 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.37 (m, 1H), 7.16 (m, 2H), 7.05 (tdd, J 
= 8.4, 2.5, 1.0 Hz, 1H), 5.05 (m, 1H), 4.64-4.31 (m, 2H), 2.57 (br s, 1H); 
13
C NMR (75 MHz, CDCl3): δ 
163.0 (d, J = 245.1 Hz), 140.7 (d, J = 7.5 Hz), 130.2 (d, J = 8.1 Hz), 121.9 (d, J = 2.7 Hz), 115.3 (d, J = 
21.0 Hz), 113.4 (d, J = 22.2 Hz), 86.9 (d, J = 173.6 Hz), 72.3 (d, J = 20.1 Hz); 
19
F NMR (282 MHz, 
CDCl3): δ -112.4, -221.5; [α]D
20
 = +42.3 (c 1.21, CHCl3), ee >99% (S).
27
 
1-(3-Chlorophenyl)-2-fluoroethanol (7j). Yellow oil; IR (NaCl): 3060, 2983, 2952, 1600, 1576, 
1479, 1433, 1266, 1198, 1079, 1012, 912, 789, 739, 703 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 7.43 (m, 
1H), 7.30 (m, 3H), 5.06 (m, 1H), 4.63-4.30 (m, 2H), 2.64 (br s, 1H); 
13
C NMR (75 MHz, CDCl3): δ 
140.1 (d, J = 8.0 Hz), 134.6, 129.9, 128.6, 126.5, 124.5, 86.9 (d, J = 173.7 Hz), 72.3 (d, J = 20.0 Hz); 
19
F NMR (282 MHz, CDCl3): δ -221.4; [α]D
20
 = +42.1 (c 1.65, CHCl3), ee >99% (S).
27
 
2-Fluoro-1-(3-methoxyphenyl)ethanol (7k). Light yellow oil; IR (NaCl): 3056, 2950, 2838, 1603, 
1587, 1489, 1467, 1456, 1436, 1320, 1267, 1158, 1043, 1010, 881, 786, 737, 700 cm
-1
; 
1
H NMR (300 
MHz, CDCl3): δ 7.31 (m, 1H), 6.97 (m, 2H), 6.89 (m, 1H), 5.02 (m, 1H), 4.63-4.32 (m, 2H), 3.84 (s, 
3H), 2.39 (br s, 1H); 
13
C NMR (75 MHz, CDCl3): δ 159.9, 139.7 (d, J = 8.2 Hz), 129.7, 118.5, 113.9, 
111.8, 87.2 (d, J = 173.3 Hz), 72.9 (d, J = 19.7 Hz), 55.3; 
19
F NMR (282 MHz, CDCl3): δ -220.7; MS 
 12 
(ESI
+
, m/z): 193 [(M+Na)
+
, 100%], 153 [(M-OH)
+
, 50%]; HRMS (ESI
+
, m/z) calculated for 
C9H11O2FNa (M+Na)
+
: 193.0637, found: 193.0635; [α]D
20
 = +42.3 (c 1.85, CHCl3), ee >99% (S). 
2-Fluoro-1-(3-nitrophenyl)ethanol (7l). Light yellow solid; mp: 49.9-54.8˚C; IR (NaCl): 3054, 2987, 
1534, 1422, 1353, 1265, 896, 738, 705 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 8.32 (ap t, J = 2.0 Hz, 1H), 
8.22 (ddd, J = 8.2, 2.3, 1.0 Hz, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.59 (ap t, J = 8.0 Hz, 1H), 5.16 (m, 1H), 
4.69-4.36 (m, 2H), 2.76 (br s, 1H); 
13
C NMR (75 MHz, CDCl3): δ 148.4, 140.4 (d, J = 7.6 Hz), 132.4, 
129.6, 123.3, 121.4, 86.5 (d, J = 174.2 Hz), 71.9 (d, J = 20.5 Hz); 
19
F NMR (282 MHz, CDCl3): δ          
-222.7; MS (ESI
+
, m/z): 208 [(M+Na)
+
, 100%], 186 [(M+H)
+
, 45%]; HRMS (ESI
+
, m/z) calculated for 
C8H8NO3FNa (M+Na)
+
: 208.0374, found: 208.0380; [α]D
20
 = +33.5 (c 1.04, CHCl3), ee >99% (S). 
Enzymatic screening with 3a. In a 1.5 mL Eppendorf vial, LBADH (3 U) or lyophilized cells of the 
overexpressed ADH (ADH-A, ADH-T, RasADH, SyADH, or TeSADH) in E. coli (20 mg), were added 
in Tris.HCl buffer 50 mM pH 7.5 (570 µL, 1 mM NADP
+
 for LBADH, ADH-T, RasADH, SyADH, and 
TeSADH or 1 mM NADH for ADH-A; 1 mM MgCl2 for LBADH), and mixed with 3a (30 mM) and 2-
propanol (30 μL, 5% v v-1, for LBADH, ADH-A, ADH-T, SyADH, and TeSADH) or with glucose (1.5 
M) and GDH (5 U) for RasADH. The reactions were shaken at 30ºC and 250 rpm for 24 h and stopped 
by extraction with ethyl acetate (2 x 0.5 mL). The organic layers were separated by centrifugation (2 
min, 13000 rpm) and dried over Na2SO4. Conversions of the corresponding alcohol were determined by 
GC obtaining the following results: for LBADH (>99%), E. coli/ADH-A (>99%), E. coli/RasADH 
(99%), E. coli/SyADH (4%), E. coli/ADH-T (99%), and E. coli/TeSADH (64%). 
General procedure for an enzymatic reduction using LBADH from Lactobacillus brevis. In a 1.5 
mL Eppendorf vial, LBADH (3 U) was added in Tris.HCl buffer 50 mM pH 7.5 (570 µL, 1 mM NADP
+
, 
1 mM MgCl2) and mixed with 2-propanol (30 μL, 5% v v
-1
) and the corresponding ketone (30 or 50 
mM). The reaction was shaken at 30ºC and 250 rpm for 24 h and stopped by extraction with ethyl 
acetate (2 x 0.5 mL). The organic layer was separated by centrifugation (2 min, 13000 rpm) and dried 
over Na2SO4. Conversions and ee of the corresponding alcohols were determined by GC (see Tables 1 
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and S1). For α-brominated ketones, in order to avoid undesired SN2 reactions with Tris.HCl buffer,
13
 
Tris.H2SO4 buffer 50 mM pH 7.5 (570 µL, 1 mM NADP
+
, 1 mM MgBr2) was used. 
General procedure for an enzymatic reduction using E. coli/ADH-A from Rhodococcus ruber. In 
a 1.5 mL Eppendorf vial, E. coli/ADH-A (20 mg) was added in Tris-HCl buffer 50 mM pH 7.5 (570 µL, 
1 mM NADH) and mixed with 2-propanol (30 μL, 5% v v-1) and the corresponding ketone (30 or 50 
mM). The reactions were shaken at 30ºC and 250 rpm for 24 h and stopped by extraction with ethyl 
acetate (2 x 0.5 mL). The organic layer was separated by centrifugation (2 min, 13000 rpm) and dried 
over Na2SO4. Conversions and ee of the corresponding alcohols were determined by GC (see Tables 1 
and S1). For α-brominated ketones, in order to avoid undesired SN2 reactions with Tris.HCl buffer,
13
 
Tris.H2SO4 buffer 50 mM pH 7.5 (570 µL, 1 mM NADH) was used. 
Enzymatic reduction using E. coli/ADH-A in the absence of the nicotinamide cofactor. In a 1.5 
mL Eppendorf vial, E. coli/ADH-A (20 mg) was added in Tris-HCl buffer 50 mM pH 7.5 (540 µL) and 
mixed with 2-propanol (60 μL, 10% v v-1) and the corresponding ketone (100 or 200 mM). The reactions 
were shaken at 30ºC and 250 rpm for 24 h and stopped by extraction with ethyl acetate (2 x 0.5 mL). 
The organic layer was separated by centrifugation (2 min, 13000 rpm) and dried over Na2SO4. 
Conversions and ee of the corresponding alcohols were determined by GC. 
Enzymatic reduction of ketones at 100 or 200 mM concentration using LBADH. In a 1.5 mL 
Eppendorf vial, LBADH (3 U) was added in Tris.HCl buffer 50 mM pH 7.5 (540 µL, 1 mM NADP
+
, 1 
mM MgCl2) and mixed with 2-propanol (60 μL, 10% v v
-1
) and the corresponding ketone (100-200 
mM). The reactions were shaken at 30ºC and 250 rpm for 24 h and stopped by extraction with ethyl 
acetate (2 x 1 mL). The organic layer was separated by centrifugation (2 min, 13000 rpm) and dried over 
Na2SO4. Conversions and ee of the corresponding alcohols were determined by (chiral) GC (see Table 
S1). For α-brominated ketones, in order to avoid undesired SN2 reactions with Tris.HCl buffer,
13
 
Tris.H2SO4 buffer 50 mM pH 7.5 (540 µL, 1 mM NADP
+
, 1 mM MgBr2) was used. 
Enzymatic reduction of ketones at 100 or 200 mM concentration using E. coli/ADH-A. In a 1.5 
mL Eppendorf vial, E. coli/ADH-A (20 mg) was added in Tris.HCl buffer 50 mM pH 7.5 (540 µL, 1 
 14 
mM NADH) and mixed with 2-propanol (60 μL, 10% v v-1) and the corresponding ketone (100-200 
mM). The reactions were shaken at 30ºC and 250 rpm for 24 h and stopped by extraction with ethyl 
acetate (2 x 1 mL). The organic layer was separated by centrifugation (2 min, 13000 rpm) and dried over 
Na2SO4. Conversions and ee of the corresponding alcohols were determined by (chiral) GC (see Table 
S1). For α-brominated ketones, in order to avoid undesired SN2 reactions with Tris.HCl buffer,
13
 
Tris.H2SO4 buffer 50 mM pH 7.5 (540 µL, 1 mM NADH) was used. 
Enzymatic reduction of ketones at 0.5 M concentration using LBADH. In a 1.5 mL Eppendorf 
vial, LBADH (3 U) was added in Tris.HCl buffer 50 mM pH 7.5 (480 µL, 1 mM NADP
+
, 1 mM MgCl2) 
and mixed with 2-propanol (120 μL, 20% v v-1) and the corresponding ketone (0.5 M). The reaction was 
shaken at 30ºC and 250 rpm for 24 h and stopped by extraction with ethyl acetate (2 x 0.5 mL). The 
organic layer was separated by centrifugation (2 min, 13000 rpm) and dried over Na2SO4. Conversions 
and ee of the corresponding alcohols were determined by GC (see Figure 1 and Table S1). For α-
brominated ketones, in order to avoid undesired SN2 reactions with Tris.HCl buffer,
13
 Tris.H2SO4 buffer 
50 mM pH 7.5 (480 µL, 1 mM NADP
+
, 1 mM MgBr2) was used. 
Scale-up of the bioreductions using LBADH. In a 10 mL glass vial, LBADH (15 U) was added in 
Tris.HCl buffer 50 mM pH 7.5 (1 mM NADP
+
, 1 mM MgCl2) and mixed with 2-propanol (10% v v
-1
) 
and the corresponding ketone (50 mg, 100 mM). The reaction was shaken at 30ºC and 250 rpm for 24 h 
and stopped by extraction with diethyl ether (2 x 5 mL). The organic layer was dried over Na2SO4 and 
the solvent was carefully evaporated (CAUTION: fluorohydrins are highly volatile). Conversions and ee 
of the corresponding alcohols were determined by GC and NMR. For 2i, in order to avoid undesired SN2 
reactions with Tris.HCl buffer,
13
 Tris.H2SO4 buffer 50 mM pH 7.5 (1 mM NADP
+
, 1 mM MgBr2) was 
used. In most cases, the final enantiopure products exhibited excellent purity after solvent evaporation, 
so no further purification was necessary. To obtain (S)-6i, (S)-7f and (S)-7j, flash chromatography was 
employed to purify the alcohol derivatives. (S)-6i (37 mg, 73% yield, >99% ee), (S)-7a (47 mg, 93% 
yield, >99% ee), (S)-7b (44 mg, 87% yield, >99% ee), (S)-7c (36 mg, 71% yield, >99% ee), (S)-7d (46 
mg, 91% yield, >99% ee), (S)-7e (44 mg, 87% yield, >99% ee), (S)-7f (33 mg, 64% yield, >99% ee), 
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(S)-7g (48 mg, 94% yield, >99% ee), (S)-7h (48 mg, 95% yield, >99% ee), (S)-7i (42 mg, 83% yield, 
>99% ee), (S)-7j (36 mg, 71% yield, >99% ee), (S)-7k (41 mg, 81% yield, >99% ee), (S)-7l (45 mg, 
88% yield, >99% ee), (S)-8 (42 mg, 83% yield, >99% ee), and (S)-9 (43 mg, 85% yield, >99% ee). 
Scale-up of the bioreduction of ketone 2b employing E. coli/ADH-A. In a 25 mL Erlenmeyer flask, 
E. coli/ADH-A (460 mg) was added in Tris.H2SO4 buffer 50 mM pH 7.5 (10.8 mL, 1 mM NADH) and 
mixed with 2-propanol (1.2 mL, 10% v v
-1
) and ketone 2b (260 mg, 100 mM). Reactions were shaken at 
30ºC and 250 rpm for 24 h. After that time the pellet was separated by centrifugation (15 min, 6000 
rpm) and extracted with ethyl acetate (3 x 20 mL). The organic layers were combined and dried over 
Na2SO4. The solvent was evaporated and the crude was purified by flash chromatography. Isolated yield 
of (R)-6b: 184 mg, 70%, >99% ee. 
2-Bromo-1-(4-fluorophenyl)ethanol (6b).
23
 
1
H NMR (300 MHz, CDCl3): δ 7.39 (m, 2H), 7.08 (ap t, 
J = 8.7 Hz, 2H), 4.93 (m, 1H), 3.65-3.50 (m, 2H), 2.72 (d, J = 3.2 Hz); 
13
C NMR (75 MHz, CDCl3): δ 
162.6 (d, J = 245.3 Hz), 136.0 (d, J = 3.0 Hz), 127.7 (d, J = 8.3 Hz), 115.6 (d, J = 21.4 Hz), 73.2, 40.1; 
19
F NMR (282 MHz, CDCl3): δ -113.4. 
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